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Abstract 
Background: Though extensive literature on the relationship between chronic inflammation 
and health outcomes has been published, the same level of attention has not been directed 
towards the identification of clinical and behavioral risk factors on chronic inflammation as 
an outcome in marginalized populations. These populations include intravenous drug users 
(IVDU) and individuals with HIV/Hepatitis C (HCV), whose underlying conditions may 
amplify the effects of chronic inflammation on the body. The pathophysiology of chronic 
inflammation on cardiovascular health and mortality has been well established, yet the 
identification of modifiable risk factors that can be targeted for public health interventions is 
of utmost importance to reduce disease burden associated with chronic inflammation. Data 
on inflammatory biomarkers TNFR1, TNFR2, and neopterin have recently become available 
through the AIDS Linked to IntraVenous Experience (ALIVE) study, and provide a potential 
surrogate measure that may be used to ascertain contributing factors for chronic 
inflammation.  
 
Methods:  We conducted a cross-sectional study of ALIVE participants to investigate 
correlates of elevated inflammatory biomarker levels. ALIVE is a prospective cohort that is 
comprised of current and former intravenous drug users in Baltimore, Maryland. In total, 
there were 1,191 participants in this analysis, and demographic information was collected 
through the use of questionnaires administered by trained interviewers. Self-report of drug 
use and risk behaviors were obtained through standardized computer-aided questionnaire. 
For inflammatory biomarker data collection, two duplicate measurements in subjects were 
taken for each biomarker to derive an average value, with average measurements 
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subsequently log-transformed. Multivariable linear regressions were conducted comparing 
biomarker level to potential correlates. Additional analysis with HIV and HCV-specific 
covariates on biomarker concentration was carried out in HIV and HCV positive populations 
respectively to elucidate further trends within these at-risk groups. 
 
Results: Of the 1,191 ALIVE participants, 322 (27%) were HIV seropositive and 1025 (86%) 
were HCV seropositive. The mean age was 46.8 years (SD: 7.9 years) and among the 
participants, 420 (35%) were female and 1043 (88%) were African American. 252 (21%) 
reported using intravenous drugs more than once a day, and the median number of 
comorbidities in the population was 1 (IQR: 1, 2). In the overall multivariate model, three 
key covariates were found to be strongly positively associated with TNFR1, TNFR2, and 
neopterin. These variables were number of non-AIDS-related comorbidities, daily 
intravenous drug use, and HCV/HIV status. Notably, age was only significantly associated in 
TNFR1 (β = 0.05, 95% CI: 0.021 - 0.079). HCV and HIV-positive patients were stratified 
and analyzed further to better understand covariates of interest that are of unique relevance to 
these populations. In the HCV subgroup, Fibroscan score showed a strong, positive 
association with neopterin (β = 0.541, 95% CI: 0.095 - 0.987), TNFR1 (β = 0.458, 95% CI: 
0.172 - 0.743), and TNFR2 (β = 0.884, 95% CI: 0.538 - 1.229) after adjustment while HCV 
viral load, past hepatitis treatment, and ALT level were insignificant with inflammatory 
biomarker level. In the HIV subgroup, HIV viral load was statistically significant for 
neopterin (β = 0.236, 95% CI: 0.147 - 0.324) and TNFR2 (β = 0.123, 95% CI: 0.049 - 0.196), 
while HAART treatment in the past six months and CD4 nadir were not observed to possess 
any meaningful association with biomarker level. 
iv 
 
Conclusions: The association between chronic inflammation and negative health outcomes 
has been discussed extensively throughout the scientific literature, but there is a vital need to 
recognize risk factors that contribute to elevated inflammation. The determination of 
modifiable risk factors is a public health imperative, and our results suggest several 
behavioral and clinical areas of focus that may be suitable for further intervention efforts. In 
our analysis, we identified several variables that show significant relationships with the 
inflammatory biomarkers of interest. In particular, our findings suggest that intravenous drug 
usage, non-AIDS-defining comorbidities, and HCV/HIV status show consistent statistical 
significance in their associations with higher levels of TNFR1, TNFR2, and neopterin. We 
noticed that within the HCV and HIV subgroups, additional strong positive relationships 
were present. Liver fibrosis was found to be closely linked with increased biomarker 
concentrations among HCV-positive subjects, while HIV viral load saw similarly significant 
associations with increased neopterin and TNFR2 levels that bring to light the additional 
impact of HIV-specific factors on chronic inflammation. This study served to identify 
potential modifiable lifestyle factors that may be targeted through public health intervention, 
in particular within at-risk IVDU and HIV/HCV-infected populations. Efforts to reduce 
injection drug use, treat underlying comorbidities such as hypertension, and increase access 
to antiretroviral treatments will be beneficial, and together may moderate cardiovascular 
disease, mortality, and other chronic inflammation-related conditions. 
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Recent literature has evaluated commonly employed markers of systemic inflammation and 
immune activation in the context of HIV and Hepatitis C infected populations.
1–4
 Of interest 
with chronic inflammation has been its pathological contributions among elderly adults, and 
attempts have been made to expand that insight into additional subgroups. From Salter et al.,
4
 
elevated interleukin-6 (IL6) levels were found in HIV and Hepatitis C infected individuals, 
yet C-reactive protein (CRP) was observed to have the opposite effect. Furthermore, injection 
drug use intensity was associated with higher levels of both IL6 and CRP. Though much has 
been discussed of the relationship between chronic inflammation and health outcomes, 
particularly in aging populations,
5–7
 the same attention has not been directed towards the 
identification of clinical and behavioral risk factors on chronic inflammation as an outcome.  
 
The pathophysiology of chronic inflammation on cardiovascular health and mortality has 
been well established,
8–12
 yet it is important now for the focus to shift towards identifying 
modifiable risk factors that can be targeted for public health interventions. In doing so, we 
look to expand the insight provided by IL6 and CRP through better understanding more 
proximate inflammatory biomarkers with TNFR1/TNFR2 and upstream immune activation 
markers with neopterin. TNFR1/TNFR2 are tumor necrosis factor (TNF) receptors that are 
responsible for propagating signals responsible for a number of cellular responses,
13
 in 
particular those associated with inflammation and infectious disease.
14,15
 TNFR2 in particular 
has commonly been used as a clinically relevant biomarker within the HIV literature, and 






The recent availability of these additional markers has provided a novel opportunity to 
further our understanding of the contributing factors for chronic inflammation. The utility of 
inflammatory biomarkers and immune activation markers is due to their potential in serving 
as rational endpoints within clinical trials focusing on chronic inflammation, and we have 
based our analysis upon this premise. To investigate correlates of elevated inflammatory 
biomarker levels, we conducted a cross-sectional study of intravenous drug users from the 
ongoing AIDS Linked to IntraVenous Experience (ALIVE) cohort whose exposure and 




The ALIVE study is a prospective cohort that is comprised of current and former intravenous 
drug users in Baltimore, Maryland.
21
 Initial recruitment for ALIVE commenced in 1988, and 
since then there have been four additional recruitment waves (1994, 1998, 2000, 2005), with 
an overall retention rate of >95%. Subjects are >17 years old and recruited from clinical 
treatment settings, and they participate in semi-annual visits comprising of medical 
examination and interview, behavioral assessments for risk behaviors including drug use, and 
collection of blood samples and other specimens. In total, there were 1,191 participants in 
this analysis; exclusion criteria for this study included CRP > 100 mg/L (n = 3), infection 
within 28 days of biomarker testing (n = 8), and missing data on 2 out of 6 measured 
comorbidities defined further in Supplemental Table 1. This research was approved by Johns 
3 
Hopkins Institution Review Boards, and all participants provided written consent for their 
participation in the study. 
 
Data Collection 
Demographic information was collected through the use of questionnaires administered by 
trained interviewers. Additional self-report data for HAART use, defined as taking three or 
more antiretroviral drugs, was provided through similar means. Self-report of drug use and 
risk behaviors were obtained through standardized computer-aided questionnaire. 
 
Neopterin, TNFR1, and TNFR2 were collected using ELISA kits and stored at 80 degrees 
Celsius throughout the duration of the study. Two duplicate measurements in subjects were 
taken for each biomarker to find an average value, and the measurements were repeated in 
the event that the two measurements differed greater than 15%.  
 
Standard laboratory procedures were carried out for determination of HIV and HCV 
serostatus, and the ascertainment of HIV and HCV RNA was conducted using commercially 
available tests. For HIV RNA measurements, ELISA, T-Cell subset assays, and real-time 
PCR were utilized. HCV infection was initially ascertained with HCV 3.0 enzyme 
immunoassay, and further confirmatory testing of HCV RNA was analyzed through 
confirmatory testing with reverse transcriptase PCR in a sub-sample of the study population 
(n = 999). CD4 cell counts and liver enzyme testing were additionally examined through 
routine laboratory assays. 
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Guidelines for comorbidity measurement were established from a prior analysis.
1
 We 
selected six non-AIDS-defining comorbidities including anemia, chronic kidney disease, 
diabetes, fibrosis, hypertension, and obstructive lung disease, and created a variable for the 
number of comorbidities within each subject. Further measurements were done for liver 
stiffness, provided by Fibroscan machine through transient elastography, and alanine 
aminotransferase testing, utilizing the Olympus 5200 Multichannel Chemistry Analyzer with 
an upper limit of 30 U/L in males and 19 U/L for females. 
 
Statistical Analysis 
The inflammatory biomarkers TNFR1, TNFR2, and neopterin were log transformed and 
assessed continuously to account for influential effects of outlying values and assist with the 
interpretation of our findings. Similar log transformations were conducted for HIV and HCV 
viral load. Through literature review and other empirical methods, potential variables 
believed to be correlates of biomarker level were identified. Univariate regression was 
performed initially to determine potentially significant factors for inclusion in the 
multivariate model. Linear regression models were used in the univariate and multivariate 
regressions, and bootstrapping was implemented in the final models to account for non-
normally distributed residuals and estimate 95% confidence intervals. The final multivariate 
model was constructed using Akaike's Information Criterion (AIC) during model selection, 
while fixing demographic characteristics of interest such as age, sex, and race.  
 
Looking within the HIV and HCV positive populations, additional analysis with HIV and 
HCV-specific variables on biomarker level was carried out to elucidate further trends within 
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these at-risk groups. Univariate regressions were conducted in a similar fashion to the overall 
model, with initial selection of HIV and HCV subgroup variables informed by review of 
corresponding literature. For the HIV subgroup, HIV viral load and CD4 count were included 
while for the HCV subgroup, HCV viral load, ALT, and Fibroscan values were analyzed. To 
address the influence of past versus current exposures, CD4 nadir was included in the 
multivariate models for the HIV subgroup alongside the aforementioned variables. 
 
Marginal (p < .1) and statistical significance (p < .05) were assessed on the bootstrapped 
models to identify risk factors. All analyses were conducted using STATA 12.1 (StataCorp, 




Of the 1,191 ALIVE participants, 322 (27%) were HIV seropositive and 1025 (86%) were 
HCV seropositive (Table 1). The mean age was 46.8 years (SD: 7.9 years), and among the 
participants 420 (35%) were female and 1043 (88%) were African American, with 187 (16%) 
reporting themselves as homeless in the past 6 months. 252 (21%) reported using intravenous 
drugs more than once a day, with 636 (53%) reporting alcohol use more than once a day. The 
median number of comorbidities in the population was 1 (IQR: 1, 2), and 249 (22%) had a 
BMI greater than 30 indicating obesity. For the outcome biomaker variables, neopterin had a 
mean of 16.54 (95% CI: 10.88, 27.09), TNFR1 had a mean of 1494.55 (95% CI: 1261.93, 




From Table 2, we identified several categories of potential correlates. These were divided 
into four categories: demographic, drug use, clinical outcomes, and HCV/HIV variable. Age 
was found to be positively associated for each biomarker, with less consistent results for sex 
and race. Greater than daily use of intravenous drugs was found to carry consistent levels of 
significance, with various degrees of significance in alcohol and cigarette use. ALT, 
comorbidities, Fibroscan, and many other clinical measurements were found to have 
significance across the biomarkers. In neopterin and TNFR2, CD4 count and CD4 nadir were 
found to be strongly significant, though that significance was not replicated in TNFR1. This 
trend stays consistent in the HCV/HIV category, with HIV viral load positively associated in 
continuous and categorical format. Notably, HCV serostatus was significantly positively 
associated in each biomarker, along with similar trends in significance for the continuous and 
categorical HCV viral load variables. 
 
Multivariate Associations 
In the multivariate model, three key covariates were found to be strongly associated with 
neopterin, TNFR1, and TNFR2. These variables were number of non-AIDS-related 
comorbidities, daily intravenous drug use, and HCV/HIV status. According to Table 3, each 
additional non-AIDS-related comorbidity present within the body was linked to higher mean 
loge concentrations of neopterin (0.072, 95% CI: 0.039 - 0.105), TNFR1 (0.077, 95% CI: 
0.057 - 0.097), and TNFR2 (0.109, 95% CI: 0.083 - 0.134). Greater than daily use of 
intravenous drugs was found to be associated with increased mean loge concentrations of 
each biomarker, with larger effect sizes observed in neopterin (0.134, 95% CI: 0.051 - 0.217) 
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and TNFR2 (0.123, 95% CI: 0.059 - 0.187) as compared to the marginally significant 
relationship in TNFR1 (0.046, 95% CI: -0.001 - 0.094). HCV-infected subjects were reported 
to have higher mean concentration of all three biomarkers when compared with uninfected 
subjects, while HIV-infected patients were observed to have heightened neopterin (0.431, 95% 
CI: 0.345 - 0.517) and TNFR2 (0.327, 95% CI: 0.263 - 0.390) levels as compared to the 
HIV-uninfected. 
 
Associations between biomarker concentration and other covariates were found to be more 
heterogeneous. Age was only significantly associated in TNFR1 with an increase of 0.050 
mean loge concentrations per year (95% CI: 0.021 - 0.079), while African Americans were 
shown to have lower levels of TNFR1 (-0.152, 95% CI: -0.205 - -0.098) and TNFR2 (-0.132, 
95% CI: -0.199 - -0.065) but not neopterin (-0.067, 95% CI: -0.172 - 0.039). No consistent 
trends were observed in other demographic and clinical variables such as sex and BMI. 
Additional drug variables such as alcohol and cigarette use were similarly observed to be 
discordant across the biomarkers under investigation. Greater than daily alcohol intake was 
found to be negatively associated with TNFR1 (-0.045, 95% CI: -0.083 - -0.008) while 
sharing no relationship with neopterin and TNFR2. Similarly, cigarette use in the past six 
months was negatively linked with neopterin (-0.224, 95% CI: -0.316 - -0.133), yet was not 
significantly associated with TNFR1 (0.003, 95% CI: -0.059 - 0.064) and TNFR2 (0.010, 95% 
CI: -0.066 - 0.087). 
 
HCV and HIV Subgroup Analysis 
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HCV and HIV-positive patients were stratified and analyzed further to better understand 
covariates of interest that are of unique relevance to these populations. The HCV subgroup 
consisted of 1025 HCV-seropositive subjects, while the HIV subgroup was made up of 322 
HIV-positive subjects (a characteristic to note is that each HIV-positive subject was 
simultaneously co-infected with HCV in the ALIVE cohort, due to the inclusion/exclusion 
criteria for this analysis and high HCV prevalence within the study population). 
 
In the HCV subgroup, univariate associations were found between HCV viral load, ALT 
level and liver stiffness as indicated by Fibroscan (Table 4a). Fibroscan score was determined 
to have the strongest relationship with inflammatory biomarker levels, indicating that greater 
liver stiffness was linked to increased levels of neopterin (0.893, 95% CI: 0.500 - 1.287), 
TNFR1 (0.776, 95% CI: 0.564 - 0.988), and TNRF2 (1.476, 95% CI: 1.188 - 1.764). 
Furthermore, a log10 increase in HCV viral load was positively correlated with neopterin 
(0.029, 95% CI: 0.013 - 0.046), TNFR1 (0.009, 95% CI: 0.000 - 0.018), and TNFR2 (0.029, 
95% CI: 0.016 - 0.041), while subjects with ALT levels greater than 2.5 times the upper 
normal limit were observed to have heightened biomarker concentration. Through 
multivariate analysis, many of the significant relationships were mitigated (Table 4b). After 
adjustment for other covariates, Fibroscan score continued to show a strong, positive 
association with neopterin (0.541, 95% CI: 0.095 - 0.987), TNFR1 (0.458, 95% CI: 0.172 - 
0.743), and TNFR2 (0.884, 95% CI: 0.538 - 1.229), while the remaining associations in HCV 
viral load, past hepatitis treatment, and ALT level were insignificant. 
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The covariates for the HIV subgroup analysis included HIV viral load in log10, CD4 count 
per 100, and whether HAART treatment was received in the past 6 months. Consistent with 
the results from Table 3, the univariate analysis found that HIV viral load and CD4 count had 
strong associations with neopterin and TNFR2, while no statistically significant results were 
observed between HIV-specific variables and TNFR1 (Table 5a). HIV viral load was 
positively associated with the two biomarkers, while increased CD4 count was found to have 
a negative association. Upon adjustment in a multivariate model, HIV viral load remained 
statistically significant for neopterin (0.236, 95% CI: 0.147 - 0.324) and TNFR2 (0.123, 95% 
CI: 0.049 - 0.196), while the significant relationships between CD4 count and the biomarkers 
were eliminated (Table 5b). In addition, HAART treatment was not observed to possess any 
meaningful association with biomarker level, and CD4 nadir was similarly insignificant. 
 
Sensitivity Analysis 
To assess the accuracy of our results, we looked to replicate our findings by employing proxy 
variables for covariates included in our analysis. HCV and HIV serostatus were replaced with 
HCV and HIV viral load respectively, and our analyses were re-run to determine whether 
significant differences would arise when replacing with an alternate variable. The 
substitution of HCV viral load in place of HCV serostatus revealed few substantial changes 
in effect size, though IV drug use was found to be statistically significant (0.061, 95% CI: 
0.011 - 0.111) for TNFR1 when originally marginally significant (0.046, 95% CI: -0.001 - 
0.094). Similar results were seen when replacing HIV status with HIV viral load, with most 
covariates showing similar magnitude and variability regardless of HCV/HIV status variable 
utilized. In addition, heroin and cocaine use in the past six months were included in a 
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separate model alongside the intravenous drug use variable. This was performed to determine 
whether drug type influenced the relationship between intravenous drug use and the 
inflammatory biomarkers. Our results found that neither heroin or cocaine use was 
significantly associated with any of the three biomarkers, nor their inclusion did not 
noticeably affect the relationships between other covariates in the model. 
 
Discussion 
The association between chronic inflammation and negative health outcomes has been 
discussed extensively throughout the scientific literature, but there is a vital need to recognize 
risk factors that contribute to elevated levels of inflammation. The determination of 
modifiable risk factors is a public health imperative, and our results suggest several 
behavioral and clinical areas of focus that may be suitable for further intervention efforts. In 
our analysis, we identified several variables that show significant relationships with the 
inflammatory biomarkers of interest. In particular, our findings suggest that intravenous drug 
usage, non-AIDS-defining comorbidities, and HCV/HIV status show consistent marginal and 
statistical significance in their associations with neopterin, TNFR1, and TNFR2. The strength 
of association for neopterin and TNFR2 with IV drug use suggests that increased frequency 
of injection may activate an inflammatory mechanism with biological plausibility as 
elucidated in Salter et al.
4
 We noticed that within the HCV and HIV subgroups, additional 
strong positive relationships were present. Liver fibrosis demonstrated a strong positive 
relationship with neopterin, TNFR1, and TNFR2 mean log10 concentrations among HCV-
positive subjects, with a large effect size in each after adjustment for treatment and other 
clinical variables, suggesting an inflammatory pathway that may be accentuated by non-
11 
AIDS-related comorbidities. HIV viral load saw similarly significant associations with 
increased neopterin and TNFR2 levels that bring to light the added contributory effect of 
HIV-specific factors on chronic inflammation. Past investigations have advanced that the 
mechanisms for these risk factors on chronic inflammation are hypothesized to be virally-
mediated. Our findings appear to corroborate those suggestions in our findings with TNFR2; 
the close linkage of TNFR2 with immune cells in the body provides a biological basis for the 
prior assertion. 
 
Upon adjustment for other covariates, the non-significance of age with neopterin and TNFR1 
concentration was of interest. The current body of knowledge has linked aging with chronic 
inflammation via other clinical biomarkers such as C-reactive protein,
9
 yet the expected 
relationships did not manifest in our analysis. Our univariate regressions showed higher age 
being strongly significant with elevated concentration of all three biomarkers. However, the 
lack of significance with two of our biomarkers in the multivariate model was believed to be 
due to the inclusion of associated covariates possessing explanatory power for the role of age 
on chronic inflammation.  
 
In our subgroup analysis, we noticed that temporally proximate covariates appeared to show 
stronger associations with inflammatory biomarker concentrations than more distal variables. 
It is suggestible that inflammatory status is influenced more by an individual's current health 
status than their past exposures. For example, CD4 nadir was found to be inconsequential in 
affecting neopterin and TNFR1 in the univariate regression for HIV-positive subjects, and in 
the multivariate regression was not significantly associated with any biomarker (data not 
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shown). However, HIV viral load at the most recent visit was linked to significantly 
increased concentrations of neopterin and TNFR2 after adjustment for other factors. Though 
current CD4 count was similarly not significant across the three biomarkers, it is accounted 
for with the inclusion of the HIV viral load variable. Furthermore, among HCV-positive 
participants, current fibrosis level as indicated by Fibroscan was uniformly significant with 
all three biomarkers, providing additional evidence of stronger relationships with recent 
conditions. The larger effect of current status on inflammatory biomarker levels indicates that 
recent events may be more influential than those that have occurred in the past. Nevertheless, 
additional inquiry will be necessary on other distal variables to determine the extent to which 
temporality may affect a covariate's association with biomarker concentration. 
 
Of note, we find that TNFR2 has been shown to be a consistent biomarker in the ALIVE 
cohort, reflecting systemic inflammation with respect to HIV and HCV as opposed to TNFR1 
which has demonstrated greater variability in its associations. TNFR2 has been found to be 
primarily expressed upon monocytes and macrophages along with other immune cells, 
whereas TNFR1 is generally observed across all nucleated cell types.
22
 From there, we 
anticipate a higher magnitude of effect to be observed with increasing HIV and HCV load on 
TNFR2 level due to the immune response from the body. The role of neopterin in immune 
activation is similarly relevant as its production by monocytes and macrophages in response 
to interferon-γ (IFN-γ) suggest a biologically consistent pathway to TNFR2 that was 
corroborated by our analysis.
23
 Previous reports have suggested a relationship between 
detectable levels of HIV and HCV RNA with chronic inflammation, hypothesized through 
activation of tissue factor pathways and other inflammatory changes.
3,24
 We anticipate that 
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injection intensity and non-AIDS-related comorbid diseases may function partly through 
mediating increased immune activation through a similar pathway, though further 
investigation will be necessary to better elucidate these biological mechanisms. 
 
There are several limitations that arose over the course of our study to be addressed in future 
analyses. By design, the cross-sectional nature of our investigation does not provide 
temporality to allow for more substantive determinations of causality. Biomarkers 
concentrations were collected with one visit, which precluded us from investigating changes 
based on baseline characteristics and may not be representative of a subject's true status. Past 
investigations have suggested  that variability of biomarker level may exist over time,
25
 yet 
previous research has found that the extent of reproducibility with other markers is high.
1,2
 
Future inquiry may benefit from additional follow-up to mitigate and account for individual 
variation. We are further limited by the low number of subjects reporting to as non-African 
American and female, as well as the older ages captured in our cohort, limiting the extent to 
which we may be able to generalize our results towards the IV drug using population. Few 
distal variables were available to investigate the effect of recent vs. past exposures on 
biomarker levels, and a more comprehensive set of covariates encapsulating each category 
would provide the basis for further study. 
 
In all, we have found several factors that may impact the level of neopterin, TNFR1, and 
TNFR2 inflammatory biomarker in the body. We cited intensity of IV drug use, number of 
non-AIDS-related comorbidities, and HCV/HIV status as the primary contributors of 
elevated inflammation within our study. Our subgroup analysis has suggested that clinical 
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variables such as liver stiffness and HIV viral load in HCV and HIV-specific populations, 
respectively, contribute additionally to the burden of chronic inflammation in these marginal 
groups. The impact of chronic inflammation on negative health outcomes is of great 
importance as HCV and HIV-infected populations continue to age. However, insights into 
risk factors affecting chronic inflammation have not been as forthcoming. This study was 
conducted to shed additional light on this realm and give further impetus on potential 
modifiable lifestyle factors that may be targeted through public health intervention in an 
effort to address the effects of systemic inflammation in the population. Efforts to reduce IV 
drug use, treat underlying comorbidities such as hypertension, and increase access to 
antiretroviral treatments will be beneficial, and together carry the potential to mitigate 
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Table 1: Participant characteristics (discuss whether to add additional columns for comparison) 
 Overall (N=1191) 
Demographics   
Age, mean [SD] 46.76 [7.9] 
Female 0.35 
African American 0.88 
Married, ever 0.35 
Employed 0.26 
Homeless 0.16 
Drug Use   
Cigarette Use 0.84 
Alcohol Use, >= 1 day/week 0.53 
Injection Drug Use Frequency   
<Daily 0.79 
>Daily 0.21 





Number of Comorbidities, median [IQR] 1 [1,2] 





Obstructive Lung Disease 0.16 
HCV/HIV Status   
HCV Positive 0.86 
HIV Positive 0.27 
Inflammatory Biomarkers   
Neopterin, median [IQR] (pg/ml) 16.54 [10.88,27.09] 
TNFR1 1494.55 [1261.93,1848.23] 




Table 2: Univariate associations with covariates of interest 
 Neopterin (pg/ml in log scale) TNFR1 (pg/ml in log scale) TNFR2 (pg/ml in log scale) 
Demographic    
Age 0.005502** 0.00591** 0.00483** 
Female -0.09875** 0.021693 0.025011 
African American 0.027174 -0.09342** -0.05116 
Employed -0.05469 -0.07172** -0.14273** 
Drug Use    
Alcohol Frequency (> Daily) -0.0786** -0.0425** -0.03387 
Cigarette Use (>Daily) -0.22091** -0.00111 0.022524 
Crack Use -0.10398** -0.05109** -0.07494** 
IV Drug Use (>daily) 0.08942* 0.0446* 0.1138** 
Clinical Outcomes    
ALT 0.002141** 0.000669** 0.002173** 
AST 0.00269** 0.001017** 0.003231** 
CD4 Nadir -0.00063** -5.40E-05 -0.00055** 
CD4 Cell Count -0.00054** 1.30E-05 -0.00041** 
Comorbidities 0.12304** 0.085097** 0.15188** 
Fibroscan (log) 0.22096** 0.1701** 0.3284** 
Obese -0.0787 0.049** -0.03553 
HCV/HIV Variables    
HCV Positive 0.525263** 0.195743** 0.438942** 
HCV VL .0810505** .00008 .0581367** 
HCV VL Category (>40) .3473** .1235** .30152** 
HIV Positive 0.52207** 0.025385 0.426742** 
HIV VL 0.2483** 0.01151 0.13811** 
HIV (undetectable)  0.23664** 0.02947 0.32777** 
HIV (detectable) 0.75009** 0.02213 0.50581** 
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HIV (CD4<350) 0.6395** 0.0226 0.4779** 
HIV (CD4>350) 0.3573** 0.0293 0.355** 




Table 3: Risk factor associations with inflammatory biomarkers 
 Neopterin (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR1 (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR2 (pg/ml in log scale) 
β coefficient (95% CI)1 
Demographics    
Age -0.002 (-0.047 - 0.043) 0.050 (0.021 - 0.079)** 0.021 (-0.014 - 0.055) 
Sex    
    Male REF REF REF 
    Female -0.058 (-0.132 - 0.015) 0.035 (-0.009 - 0.080) 0.037 (-0.020 - 0.093) 
Race    
    White/other REF REF REF 
    African American -0.067 (-0.172 - 0.039) -0.152 (-0.205 - -0.098)** -0.132 (-0.199 - -0.065)** 
Drug Use    
IV Drug Use    
    <Daily REF REF REF 
    >Daily 0.134 (0.051 - 0.217)** 0.046 (-0.001 - 0.094)* 0.123 (0.059 - 0.187)** 
Daily Alcohol Intake    
   <1 day/week REF REF REF 
   >1 day/week -0.028 (-0.098 - 0.042) -0.045 (-0.083 - -0.008)** -0.015 (-0.065 - 0.034) 
Current Cigarette Use    
    No REF REF REF 
    Yes -0.224 (-0.316 - -0.133)** 0.003 (-0.059 - 0.064) 0.010 (-0.066 - 0.087) 
Clinical Outcomes    
BMI    
    <25 REF REF REF 
     25-30 -0.044 (-0.121 - 0.032) 0.013 (-0.033 - 0.059) -0.029 (-0.088 - 0.029) 
    >30 -0.087 (-0.179 - 0.004)* 0.046 (-0.007 - 0.099)* 0.001 (-0.065 - 0.066) 
Comorbidities 0.072 (0.039 - 0.105)** 0.077 (0.057 - 0.097)** 0.109 (0.083 - 0.134)** 
HCV Status    
    Uninfected REF REF REF 
    HCV Positive 0.347 (0.263 - 0.431)** 0.144 (0.097 - 0.191)** 0.266 (0.206 - 0.327)** 
HIV Status    
    Uninfected REF REF REF 
    HIV Positive 0.431 (0.345 - 0.517)** -0.034 (-0.081 - 0.014) 0.327 (0.263 - 0.390)** 
 
*Marginal significance: p<0.1 
**Statistical significance: p<0.05  
1
β coefficients estimated using linear regression, and 95% CIs estimated from bootstrapping using 1000 replications to account for 
non-Gaussian residuals.  
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Table 4a: HCV subgroup analysis among 1025 HCV-seropositive participants (Univariate) 
 Neopterin (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR1 (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR2 (pg/ml in log scale) 
β coefficient (95% CI)1 
HCV VL2 0.029 (0.013 - 0.046)** 0.009 (0.000 - 0.018)** 0.029 (0.016 - 0.041)** 
Hepatitis C Treatment    
Never Received REF REF REF 
Has Received 0.016 (-0.187 - 0.219) 0.004 (-0.107 - 0.116) 0.007 (-0.146 - 0.160) 
ALT (ULN)    
<1.5 REF REF REF 
1.5-2.5 0.150 (0.054 - 0.246)** 0.041 (-0.011 - 0.005) 0.098 (0.026 - 0.171)** 
>2.5 0.148 (0.040 - 0.255)** 0.063 (0.005 - 0.120)** 0.196 (0.115 - 0.276)** 
Fibroscan2 0.893 (0.500 - 1.287)** 0.776 (0.564 - 0.988)** 1.476 (1.188 - 1.764)** 
 
*Statistically significant at p<0.05  
1
β coefficients estimated using linear regression, and 95% CIs estimated from bootstrapping using 1000 replications to account  for 
non-Gaussian residuals. 
2





Table 4b: HCV subgroup analysis among 1025 HCV-seropositive participants (Multivariate) 
 Neopterin (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR1 (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR2 (pg/ml in log scale) 
β coefficient (95% CI)1 
HCV VL2 0.014 (-0.003 - 0.032) 0.008 (-0.003 - 0.018) 0.015 (0.002 - 0.028)** 
Hepatitis C Treatment    
Never Received REF REF REF 
Has Received -0.047 (-0.254 - 0.159) 0.002 (-0.109 - 0.113) -0.021 (-0.168 - 0.126) 
ALT (ULN)    
<1.5 REF REF REF 
1.5-2.5 0.054 (-0.055 - 0.164) -0.036 (-0.093 - 0.022) -0.031 (-0.109 - 0.047) 
>2.5 0.023 (-0.099 - 0.145) -0.022 (-0.086 - 0.042) 0.033 (-0.050 - 0.117) 
Fibroscan2 0.541 (0.095 - 0.987)** 0.458 (0.172 - 0.743)** 0.884 (0.538 - 1.229)** 
Adjusted for age, sex, race, BMI, comorbidity, IV drug use, alcohol, cigarette, HIV status 
 
*Marginal significance: p<0.1 
**Statistical significance: p<0.05  
1
β coefficients estimated using linear regression, and 95% CIs estimated from bootstrapping using 1000 replications to account  for 
non-Gaussian residuals. 
2





Table 5a: HIV subgroup analysis among 322 HIV-positive participants (Univariate) 
  Neopterin (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR1 (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR2 (pg/ml in log scale) 
β coefficient (95% CI)1 
HIV VL2 0.251 (0.185 - 0.316)** 0.013 (-0.026 - 0.053) 0.138 (0.085 - 0.191)** 
CD4 Count (per 100) -0.056 (-0.088 - -0.024)** -0.010 (-0.028 - 0.008) -0.045 (-0.069 - -0.020)** 
Received HAART 
within last 6 months 
   
No REF REF REF 
Yes -0.233 (-0.377 - -0.088)** 0.071 (-0.011 - 0.153)* -0.081 (-0.193 - 0.032) 
*Marginal significance: p<0.1 
**Statistical significance: p<0.05  
1
β coefficients estimated using linear regression, and 95% CIs estimated from bootstrapping using 1000 replications to account  for 
non-Gaussian residuals. 
2





Table 5b: HIV subgroup analysis among 322 HIV-positive participants (Multivariate) 
  Neopterin (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR1 (pg/ml in log scale) 
β coefficient (95% CI)1 
TNFR2 (pg/ml in log scale) 
β coefficient (95% CI)1 
HIV VL2 0.236 (0.147 - 0.324)** 0.029 (-0.022 - 0.081) 0.123 (0.049 - 0.196)** 
CD4 Count (per 100) 0.003 (-0.033 - 0.039) -0.001 (-0.023 - 0.022) -0.012 (-0.043 - 0.019) 
Received HAART 
within last 6 months 
   
No REF REF REF 
Yes -0.035 (-0.204 - 0.134) 0.097 (-0.004 - 0.199)* 0.029 (-0.107 - 0.166) 
Adjusted for age, sex, race, BMI, comorbidity, IV drug use, alcohol, cigarette, HIV status 
 
*Marginal significance: p<0.1 
**Statistical significance: p<0.05  
1
β coefficients estimated using linear regression, and 95% CIs estimated from bootstrapping using 1000 replications to account  for 
non-Gaussian residuals. 
2
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